Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMNM Immunome	$10.01 +1.0%	$9.59	$5.15 ▼ $16.73	$862.62M	1.93	764,200 shs	983,043 shs
TRVI Trevi Therapeutics	$7.60 +3.7%	$6.65	$2.36 ▼ $8.11	$892.62M	0.58	1.81 million shs	1.72 million shs
TVRD Tvardi Therapeutics	$23.74 +0.6%	$25.05	$8.13 ▼ $34.31	$220.92M	0.21	31,196 shs	17,500 shs
URGN Urogen Pharma	$20.11 +4.7%	$14.91	$3.42 ▼ $21.01	$888.27M	1.12	1.38 million shs	1.22 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMNM Immunome	+2.59%	-8.66%	+14.70%	+24.34%	-21.60%
TRVI Trevi Therapeutics	+0.14%	-1.08%	+11.91%	+18.42%	+168.50%
TVRD Tvardi Therapeutics	-2.20%	-9.20%	-13.68%	+2,359,999,900.00%	+2,359,999,900.00%
URGN Urogen Pharma	+5.26%	-7.34%	+34.83%	+94.53%	+32.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMNM Immunome	1.7174 of 5 stars	3.5	0.0	0.0	0.0	2.5	2.5	0.0
TRVI Trevi Therapeutics	3.0595 of 5 stars	4.7	1.0	0.0	0.0	2.6	2.5	0.0
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	4.6704 of 5 stars	4.5	4.0	0.0	4.5	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMNM Immunome	3.00	Buy	$23.14	131.20% Upside
TRVI Trevi Therapeutics	3.30	Buy	$20.38	168.09% Upside
TVRD Tvardi Therapeutics	3.00	Buy	$64.25	170.64% Upside
URGN Urogen Pharma	3.00	Buy	$31.43	56.28% Upside

Current Analyst Ratings Breakdown

Latest TVRD, IMNM, URGN, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
8/8/2025	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$29.00 ➝ $27.00
8/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $22.00
8/7/2025	IMNM Immunome	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $22.00
8/7/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00
8/5/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/14/2025	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$62.00
7/11/2025	TVRD Tvardi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$52.00
7/8/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/7/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/1/2025	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMNM Immunome	$9.04M	96.38	N/A	N/A	$3.09 per share	3.24
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.63 per share	N/A
TVRD Tvardi Therapeutics	$7.14M	31.12	N/A	N/A	($3.02) per share	-7.86
URGN Urogen Pharma	$90.40M	10.29	N/A	N/A	($2.02) per share	-9.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMNM Immunome	-$292.96M	-$3.08	N/A	N/A	N/A	-1,687.08%	-76.10%	-65.14%	N/A
TRVI Trevi Therapeutics	-$47.91M	-$0.42	N/A	N/A	N/A	N/A	-41.44%	-38.21%	N/A
TVRD Tvardi Therapeutics	-$70.87M	N/A	0.00	∞	N/A	-595.39%	-710.04%	-79.00%	N/A
URGN Urogen Pharma	-$126.87M	-$3.32	N/A	N/A	N/A	-164.44%	-97,487.15%	-59.38%	N/A

Latest TVRD, IMNM, URGN, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	TRVI Trevi Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
8/7/2025	Q2 2025	URGN Urogen Pharma	-$0.82	-$1.05	-$0.23	-$1.05	$23.06 million	$24.22 million
8/6/2025	Q2 2025	IMNM Immunome	-$0.52	-$0.50	+$0.02	-$0.50	$1.03 million	$4.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMNM Immunome	N/A	12.13	12.13
TRVI Trevi Therapeutics	N/A	22.42	22.42
TVRD Tvardi Therapeutics	N/A	32.48	31.73
URGN Urogen Pharma	N/A	4.14	3.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMNM Immunome	44.58%
TRVI Trevi Therapeutics	95.76%
TVRD Tvardi Therapeutics	44.66%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
IMNM Immunome	7.69%
TRVI Trevi Therapeutics	18.30%
TVRD Tvardi Therapeutics	3.10%
URGN Urogen Pharma	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMNM Immunome	40	87.04 million	80.35 million	Optionable
TRVI Trevi Therapeutics	20	121.78 million	99.49 million	Optionable
TVRD Tvardi Therapeutics	80	9.36 million	9.07 million	N/A
URGN Urogen Pharma	200	46.26 million	44.09 million	Optionable

TVRD, IMNM, URGN, and TRVI Headlines

Recent News About These Companies

17,571 Shares in Urogen Pharma (NASDAQ:URGN) Acquired by Persistent Asset Partners Ltd

August 13 at 7:06 AM | marketbeat.com

UroGen Pharma’s Earnings Call: Achievements and Challenges

August 13 at 2:04 AM | msn.com

Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Buy" from Brokerages

August 13 at 2:29 AM | americanbankingnews.com

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript

August 12 at 4:03 PM | msn.com

HC Wainwright Issues Pessimistic Forecast for Urogen Pharma (NASDAQ:URGN) Stock Price

August 12 at 8:22 AM | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Releases Earnings Results, Misses Expectations By $0.20 EPS

August 11 at 2:33 PM | marketbeat.com

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

August 10 at 2:34 PM | finance.yahoo.com

UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation

August 9, 2025 | seekingalpha.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% on Disappointing Earnings

August 9, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% Following Weak Earnings

August 8, 2025 | marketbeat.com

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...

August 8, 2025 | finance.yahoo.com

UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI

August 8, 2025 | tipranks.com

UroGen (URGN) Q2 Revenue Rises 11%

August 7, 2025 | aol.comA

UroGen (URGN) Q2 Revenue Rises 11%

August 7, 2025 | aol.comA

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat

August 7, 2025 | investing.com

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat

August 7, 2025 | investing.com

Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft

August 7, 2025 | tipranks.com

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

UroGen Pharma Q2 2025 Earnings Preview

August 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TVRD, IMNM, URGN, and TRVI Company Descriptions

Immunome NASDAQ:IMNM

$10.01 +0.10 (+1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$10.12 +0.11 (+1.06%)

As of 07:57 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Trevi Therapeutics NASDAQ:TRVI

$7.60 +0.27 (+3.68%)

Closing price 04:00 PM Eastern

Extended Trading

$7.60 0.00 (0.00%)

As of 07:57 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Tvardi Therapeutics NASDAQ:TVRD

$23.74 +0.14 (+0.59%)

As of 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Urogen Pharma NASDAQ:URGN

$20.11 +0.91 (+4.74%)

Closing price 04:00 PM Eastern

Extended Trading

$19.84 -0.27 (-1.32%)

As of 06:51 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time